top of page

HOLISTIC ANTIBODY DESIGN

Our unique Generative-AI platform will revolutionize your pipeline by gaining control, reducing failure uncertainty and boosting candidate's accuracy.

AT A GLANCE

Who we are

In Silica Corpora we design the next generation therapeutics Antibodies using our Generative-AI platform powered by proprietary Foundation Models for De Novo Antibody Design.

Our competitive advantage is our holistic approach capable of finding lead candidates using only amino acid sequences.

We believe each project is different, and that's why our aim is to develop tailored solutions for our partners, including lead candidates to start preclinical trials.

WHY TO CHOOSE US

Find out why Silica Corpora is your best ally for Antibody Discovery

Computer Chip

More Precision,
Less Time.

Our platform MALI makes the Drug Discovery process extremely accurate, finding the right candidates in record time and reducing the number of Antibodies to be tested experimentally in the pre-clinical trial phase.

gettyimages-1133973940-2048x2048-removeb
gettyimages-1133973940-2048x2048-removeb
gettyimages-1133973940-2048x2048-removeb
gettyimages-1133973940-2048x2048-removeb
AdobeStock_552748421.jpeg
united.png

We want to grow with you.

Aside other CRO models, Silica Corpora wants to establish long-lasting partnerships to co-develop tailored and meaningful solutions. While being able to use all our existing tools, we use your accumulated data to create your tailored models and improve the quality of your future drug candidates.

AdobeStock_216407146.jpeg

Boost accuracy without altering the process 

Our technology doesn’t disrupt existing in vitro workflows of our customers, thus, our methods can be easily plugged into established in vitro workflows with no need for new equipment, expertise, or personnel.

partner prop webpage.png

OUR UNIQUENESS

A holistic approach to reach the next generation of drug development.

Taking advantage of the progress in Generative-AI, we developed a protein-LLM that works only with AA sequences, making the characterization stage much more agile.

 

Using AI models trained on amino acid sequences we can generate more quality Antibodies from scratch, without using In Vitro nor In Vivo Methods.

bottom of page